

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 66438

Title: "New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer"

Reviewer's code: 05465567

Position: Peer Reviewer

Academic degree: MD

Professional title: Staff Physician

Reviewer's Country/Territory: Argentina

Author's Country/Territory: Spain

Manuscript submission date: 2021-03-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-03-29 03:21

Reviewer performed review: 2021-03-30 04:20

Review time: 1 Day

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Very complete review about the rol of immunotherapy and radiotherapy in lung cancer, from early stage to advanced disease.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 66438

Title: "New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer"

Reviewer's code: 05187436

Position: Peer Reviewer

Academic degree: N/A

Professional title: N/A

Reviewer's Country/Territory: Italy

Author's Country/Territory: Spain

Manuscript submission date: 2021-03-28

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-05-27 02:58

Reviewer performed review: 2021-05-27 03:05

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Authors report a review on the combination of radiotherapy and immunotherapy in non-small cell lung cancer. In my opinion the review is linear, concise and well designed written. The paper can be accepted in the present form

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 66438

Title: "New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer"

Reviewer's code: 05391712

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: India

Author's Country/Territory: Spain

Manuscript submission date: 2021-03-28

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-05-25 12:17

Reviewer performed review: 2021-05-30 12:47

Review time: 5 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The authors have presented a crisp and concise summary of the combination of immunotherapy and radiotherapy. A few additions may improve the quality of the article - A diagrammatic representation of interaction between radiotherapy and immunotherapy would be more informative and easier to understand to the reader - There should be a section devoted to the toxicity analysis of various immunotherapy agents.. or you can mention about toxicity data next to the specific trial you have written

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 66438

Title: "New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer"

Reviewer's code: 05380317

Position: Peer Reviewer

Academic degree: MD

Professional title: Assistant Professor

Reviewer's Country/Territory: India

Author's Country/Territory: Spain

Manuscript submission date: 2021-03-28

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-05-29 03:32

Reviewer performed review: 2021-06-02 05:11

Review time: 4 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Well Written, May be accepted for publication

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 66438

Title: "New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer"

Reviewer's code: 05402718

Position: Peer Reviewer

Academic degree: PhD

Professional title: Assistant Professor, Research Associate

Reviewer's Country/Territory: China

Author's Country/Territory: Spain

Manuscript submission date: 2021-03-28

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-05-26 00:35

Reviewer performed review: 2021-06-04 03:00

Review time: 9 Days and 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

In the present study, Luna et al. reviewed new challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer. Although there is some interesting, there are still some comments for the authors. 1. Introduction, "Immunotherapy in the form of immune checkpoint inhibitors (ICI) is becoming a revolution in the knowledge and treatment of cancer." Please further edit the language. 2. Introduction, the "PACIFIC" should have the full name, please supply it. 3. In the 2nd part, Atezolizumab has also shown good results in the first-line setting. Please supply the reference. 4. "6. Radio-immunotherapy in stage IV non-small-cell lung cancer", non-small-cell lung cancer should be NSCLC. 5. I hope authors cite correct references. For example, "As mentioned above, the irruption of ICI has been shifted the treatment paradigm in metastatic NSCLC by increasing survival both as first and second-line therapy [2-3], [5,7,11,31], [56-57]." This is a serious problem. 6. The current challenges of "Radio-immunotherapy in NSCLC" are necessary to be added. 7. The conclusion needs to add some information. 8. A schematic diagram should be supplied for how Radio-immunotherapy played a role in NSCLC.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 66438

Title: "New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer"

Reviewer's code: 05402718

Position: Peer Reviewer

Academic degree: PhD

Professional title: Assistant Professor, Research Associate

Reviewer's Country/Territory: China

Author's Country/Territory: Spain

Manuscript submission date: 2021-03-28

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2021-07-09 04:24

Reviewer performed review: 2021-07-10 01:32

Review time: 21 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Although the authors have made much progress, there are still some comments for them.

1. In the keywords, “immunotherapy” is a wrong word, please also check the spelling. Additionally, “evidence” makes no sense, please delete it. 2. In the section of IMMUNOTHERAPY IN LUNG CANCER, “In the updated analysis, with a median follow-up of 25.2 mo, the median OS was 30.0 mo with pembrolizumab and 14.2 mo with chemotherapy (hazard ratio –HR-, 0.63; 95%CI, 0.47 to 0.86).” What is the mean of mo, if it is the abbreviation of month, please show the full name when you first use the abbreviation. Please also check throughout the manuscript. 3. Please provide the references for it “In particular, Keynote-10 was the first to select patients with a programmed death cell protein ligand 1 (PD-L1) expression in tumor cells $\geq 1\%$, showing that a higher expression of PD-L1 tends to produce better responses.” 4. “This causes the activation of T cells into cytotoxic T cells, which can then be distributed through the bloodstream and reach distant tumor locations [20-21]. Image 1.” Why “Image 1” is an independent word, it should be a sentences. The language still needs to be improved for the basic writing skill.